Sponsor:
Northwestern University
Code:
NCT07594548
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Futibatinib
Magnetic Resonance Imaging
Paclitaxel
Brief summary:
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Study ID
NCT07594548
Start date
Nov 10, 2026
Status verified date
Nov, 2026
Completion date
Sep 9, 2031
Anticipated
Primary completion date
Sep 9, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
18 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Treatment (futibatinib, paclitaxel, ramucirumab)
Interventions
Biospecimen Collection
Computed Tomography
Futibatinib
Magnetic Resonance Imaging
Paclitaxel
Ramucirumab
Primary outcome measure
Central contacts
Locations
Northwestern University
Recruiting
Chicago, Illinois, United States, 60611
Contacts
Principal Investigator:
Gladys Rodriguez, MD
Sponsor
Northwestern University
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Northwestern University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.